March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Severity of Ocular Surface Diseases Symptoms is Temporally Associated with the Intensity of Topical Glaucoma Therapy
Author Affiliations & Notes
  • Hamed B. Lari
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Tamara L. Berezina
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Albert S. Khouri
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Larissa A. Gregory
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Daniel Levinsohn
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Robert D. Fechtner
    Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, Newark, New Jersey
  • Footnotes
    Commercial Relationships  Hamed B. Lari, None; Tamara L. Berezina, None; Albert S. Khouri, None; Larissa A. Gregory, None; Daniel Levinsohn, None; Robert D. Fechtner, None
  • Footnotes
    Support  Supported, in part, by an Unrestricted Grant from Research to Prevent Blindness, Inc., NY, The Glaucoma Research & Education Foundation, Inc., NJ, and The Lions Eye Research Foundation of New Jersey.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4480. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hamed B. Lari, Tamara L. Berezina, Albert S. Khouri, Larissa A. Gregory, Daniel Levinsohn, Robert D. Fechtner; Severity of Ocular Surface Diseases Symptoms is Temporally Associated with the Intensity of Topical Glaucoma Therapy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4480.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Glaucoma topical therapy is associated with ocular surface disease (OSD). To examine the temporal correlation between OSD symptoms and the duration and intensity of topical glaucoma therapy.

 
Methods:
 

This was a prospective controlled cross-sectional study. Patients on non-glaucoma topical therapy, ocular surgery within 3 years, and diagnosis of OSD were excluded. 62 patients were enrolled (32 on topical therapy, 30 controls). The Ocular Surface Disease Index (OSDI) questionnaire (score 0-100, 0=no symptoms, 100=maximum symptoms) was administered for each patient. Main outcome measures were OSDI scores, duration of topical therapy, total number of applied drops, and a drop-year exposure index (drops/week × therapy duration in yrs). For each patient, the eye with longer therapy duration was chosen. In patients with equally treated eyes, one eye was randomly selected.

 
Results:
 

Glaucoma patients used a mean of 2.1±0.88 topical medications for mean duration of 222±215 weeks (range 2-800). The mean number of applied drops was 6001±9174 drops/eye. The mean exposure index was 115 ±176 drop-year. Mean OSDI score of glaucoma patients (18.5±9.5) was greater than controls’ (6.3±5.7, P= 0.0000001). More glaucoma patients (n=22, 69%) than controls (n= 5, 17%) reported OSD symptoms (OSDI score>12, P= 0.00003). In the topical glaucoma therapy group, those with OSD symptoms had a longer mean duration of therapy, a greater number of applied drops, and a higher exposure index (Table). OSDI scores were positively correlated with the duration of topical therapy (R=0.6), total number of applied drops (R=0.49), and the exposure index (R=0.49).

 
Conclusions:
 

OSD symptoms were more prevalent in patients on topical glaucoma therapy. The severity of OSD symptoms was positively correlated with the duration and exposure intensity of topical glaucoma therapy. Patients on topical therapy for mean duration of 18 months or less did not exhibit significant OSD symptoms.  

 
Keywords: clinical (human) or epidemiologic studies: prevalence/incidence • ocular irritants • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×